Physician profile
Daniel Millard Corbin
NPI 1396253563
$13,503.14
in general payments reported to CMS, 2019-2025
26 companies · $11K in 2025
The $11K reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $808 · 2022: $277 · 2023: $673 · 2024: $447 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,988 · Food and Beverage: $1,885 · Travel and Lodging: $1,546.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,987.50 |
| Food and Beverage | $1,885.33 |
| Travel and Lodging | $1,545.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11,466.25 | 2021-2025 | Yeztugo, Descovy |
| Novo Nordisk INC | $369.99 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $346.44 | 2021-2024 | Repatha, Otezla |
| Astrazeneca Pharmaceuticals LP | $186.03 | 2021-2025 | Farxiga, Airsupra |
| Abbott Laboratories | $164.14 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Lilly USA, LLC | $145.64 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $124.26 | 2021-2023 | |
| Supernus Pharmaceuticals, INC. | $114.29 | 2023-2025 | Qelbree, Qelbree, Xyosted |
| Pfizer INC. | $92.09 | 2021-2024 | |
| Sanofi-Aventis U.S. LLC | $61.29 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.88 | 2021-2023 | |
| Exact Sciences Corporation | $41.73 | 2023-2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $40.99 | 2023 | Abilify Asimtufii, Rexulti |
| Amarin Pharma, INC. | $36.51 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.16 | 2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Currax Pharmaceuticals LLC | $32.53 | 2021-2025 | Contrave |
| Merck Sharp & Dohme LLC | $29.14 | 2021-2024 | Gardasil, Gardasil 9, Capvaxive |
| Viiv Healthcare Company | $27.30 | 2025 | Apretude |
| Genentech USA, INC. | $26.61 | 2021-2022 | |
| Organon LLC | $23.05 | 2024 | |
| Halozyme INC | $17.94 | 2023 | |
| Axsome Therapeutics, INC. | $17.73 | 2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $17.15 | 2023 | Trintellix |
| Phadia US INC. | $14.98 | 2024 | Immunocap |
| Glaxosmithkline, LLC. | $13.82 | 2023 | Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $13.20 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Corbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.